Company analysis

Emerging Pharma
Big Pharma
Mid Pharma
Japan Pharma
Hot Topics
M&A Analysis

Sort by Price

Click to order products descending

Display 15 Products per page

Company Analysis: Bayer

$3,000.00

PharmaVitae explores Bayer’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Company Analysis: AstraZeneca

$3,000.00

PharmaVitae explores AstraZeneca’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more
Company Analysis : AbbVie

$3,000.00

PharmaVitae explores AbbVie’s prescription pharmaceutical performance and outlook over 2019–29.
July 15, 2020
Find out more
Big Pharma Outlook 2015

$3,000.00

Big Pharma is poised for growth due to strong launch portfolios, the availability of high-potential pipeline assets, and companies’ sharpened focus on high-performing markets.
September 28, 2016
Find out more
Orphan Drug Market Outlook to 2017

$3,000.00

Tumbling over the patent cliff, many Big Pharma companies are being forced to find new strategies for sustaining sales growth, wherever possible minimizing the risk of generic competition.
September 28, 2016
Find out more
Q2 2016 Earnings Previews

$3,000.00

Datamonitor Healthcare previews Q2 2016 earnings for companies in the PharmaVitae portfolio. Companies will be continuously added the day before presentations.
September 28, 2016
Find out more
2014 M&A Update

$3,000.00

Capital allocation and M&A continue to remain levers of growth as cash reserves grow and debt remains cheap. Many companies are looking towards core-strengthening asset purchases, low-scale asset divestments, and cost-saving tax inversions.
September 28, 2016
Find out more
2016 M&A Outlook

$3,000.00

Datamonitor Healthcare’s PharmaVitae team explores the value in the flurry of recent deals, shedding light on incentives and how they may influence the market and future deal-making. With short-term challenges seeing top line revenue from the PharmaVitae portfolio to grow by a modestly in 2016, transactions will aim to counter industry headwinds.
September 28, 2016
Find out more
Company Analysis: Mitsubishi Tanabe

$3,000.00

PharmaVitae explores Mitsubishi Tanabe’s prescription pharmaceutical performance and outlook over 2019–29.
January 29, 2021
Find out more
Company Analysis: UCB

$3,000.00

PharmaVitae explores UCB’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts
January 25, 2021
Find out more
Mid Pharma Outlook

$3,000.00

Total sales from the mid pharma peer set amounted to $69.4bn in 2011; by the end of 2012, this figure rose by 1.6% to $71.0bn. During 2012 the peer set constituents exhibited varying degrees of sales growth.
September 28, 2016
Find out more
Company Analysis: Lundbeck

$3,000.00

PharmaVitae explores Lundbeck’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more
Company Analysis: Merck KGaA

$3,000.00

PharmaVitae explores Merck KGaA’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2020
Find out more
Company Analysis: Gilead

$3,000.00

PharmaVitae explores Gilead’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more
Allergan

$3,000.00

PharmaVitae explores Allergan’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.
October 10, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *